Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)

NCT02393248 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02393248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
February 27, 2015
Completion date
December 17, 2021
Enrollment
201 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cholangiocarcinoma, endometrial cancer, gastric cancer, lung cancer, mpn, multiple myeloma, myeloproliferative neoplasms, solid tumor, uc, urothelial cancer